What question did this study set out to answer?

To investigate the influence of specific gene polymorphisms on the lipid response to rosuvastatin therapy.

January 24, 2026

Association between SLCO1B1, apolipoprotein E and ABCG2 genes and lipid response to rosuvastatin: a meta-analysis.

JLJianhai LiHuazhong Agricultural University DYDeng YuPeking University YLYong LaiYunnan Agricultural University

Puntos clave

To investigate the influence of specific gene polymorphisms on the lipid response to rosuvastatin therapy.
Conducted a meta-analysis of existing studies focusing on SLCO1B1, ApoE, and ABCG2 gene polymorphisms.
Analyzed data related to LDL-C levels in relation to these genetic variants.
Included various clinical studies examining the efficacy of rosuvastatin across different populations.
Identified that SLCO1B1, ApoE, and ABCG2 polymorphisms significantly affect LDL-C reduction.
The c.388A>G variant in SLCO1B1, along with ApoE and ABCG2 variations, shows a strong correlation with lipid response.
Individuals carrying specific polymorphisms may require adjusted rosuvastatin dosing for optimal lipid management.

Resumen

The lipid-lowering efficacy of rosuvastatin (especially the reduction of LDL-C level) is significantly affected by the polymorphisms of SLCO1B1 (c.388A>G), ApoE (c.388T>C, c.526C>T) and ABCG2 (c.421C>A) genes.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo